Topical Dapsone (Aczone): Uses, Efficacy, and How It Compares to Retinoids

What Is Topical Dapsone and How Does It Work?

Topical dapsone is a sulfone antibiotic with anti-inflammatory properties, formulated as a gel for direct application to acne-prone skin. Unlike oral dapsone (used in dermatitis herpetiformis and leprosy), the topical version delivers the drug locally with minimal systemic exposure, reducing the risk of dose-dependent blood dyscrasias 1.

The mechanism in acne centers on neutrophil suppression. Dapsone inhibits myeloperoxidase (MPO), an enzyme that generates hypochlorous acid and other reactive oxygen species within neutrophils recruited to inflamed follicles 2. By dampening this oxidative burst, dapsone reduces the redness and swelling of inflammatory papules and pustules without relying on the retinoid receptor pathway. This makes it mechanistically distinct from every topical retinoid on the market.

The FDA first approved dapsone 5% gel (Aczone) in 2005 for acne vulgaris in patients aged 12 and older 3. A reformulated 7.5% once-daily gel followed in 2016, using a modified vehicle that improved drug delivery and allowed a single daily application 4. Pharmacokinetic data from the 7.5% approval showed mean steady-state plasma concentrations of dapsone at approximately 2.3 ng/mL, well below the threshold associated with hemolytic effects from oral dosing 3.

Clinical Trial Evidence for Dapsone Gel

Two identical Phase III randomized controlled trials (N = 3,010 combined) established the efficacy of dapsone 5% gel for moderate acne. At 12 weeks, the dapsone group achieved a statistically significant improvement in Acne Global Assessment success rates (differences of 9.3% and 9.9% vs. vehicle, P<0.001 for both) 1. Inflammatory lesion counts dropped by a mean of 48.8% with dapsone 5% vs. 40.8% with vehicle.

The 7.5% formulation was evaluated in two additional key trials (N = 4,340 total). These showed a 48.9% mean reduction in inflammatory lesions and a 40.4% mean reduction in non-inflammatory lesions at week 12, both significantly superior to vehicle 4. A long-term safety study extending to 12 months demonstrated sustained efficacy with no new safety signals 5.

A pooled subgroup analysis found that female patients derived an even larger treatment effect from dapsone gel than males. In the dapsone 7.5% trials, women showed a 15.2 percentage-point advantage in Global Acne Assessment success rate vs. vehicle, compared with 8.7 points in men 6. The American Academy of Dermatology (AAD) guidelines note this sex-based differential as clinically relevant when selecting acne therapies 7.

Dapsone vs. Tretinoin (Retin-A)

Tretinoin 0.025%, 0.1% cream or gel remains one of the most widely prescribed topical acne treatments. It binds retinoic acid receptors (RAR-alpha, beta, and gamma) to normalize follicular keratinization and accelerate comedone clearance 8. A landmark 12-week trial of tretinoin 0.025% gel (N = 318) showed a 63% reduction in comedones and a 52% reduction in inflammatory lesions 9.

The tradeoff is tolerability. Tretinoin causes a well-documented retinization period of 2 to 6 weeks, marked by peeling, erythema, burning, and dryness. One comparative tolerability analysis reported that 45% of tretinoin users experienced moderate-to-severe dryness during the first month vs. under 2% with dapsone 5% gel 10. For patients with sensitive skin, rosacea-prone complexions, or darker skin tones at higher risk of post-inflammatory hyperpigmentation from retinoid irritation, dapsone offers a gentler entry point.

There is no direct head-to-head RCT comparing dapsone gel to tretinoin for acne. Clinicians typically position tretinoin as stronger for comedonal (non-inflammatory) acne and dapsone as particularly useful for inflammatory-predominant presentations or as part of combination regimens. The AAD guidelines classify both as "recommended" options for mild-to-moderate acne 7.

Dapsone vs. Adapalene (Differin)

Adapalene 0.1% gel became the first over-the-counter retinoid for acne in 2016, expanding access to retinoid therapy without a prescription 11. It selectively targets RAR-beta and RAR-gamma, producing less irritation than tretinoin while still promoting comedolysis. A key 12-week RCT (N = 653) demonstrated a 63% reduction in inflammatory lesions and 50% in non-inflammatory lesions with adapalene 0.1% gel 12.

Adapalene's tolerability advantage over tretinoin is established, but it still causes retinization in most users. A photosensitivity comparison showed that adapalene induced significantly less UV sensitivity than tretinoin (P<0.05), which matters for patients with high sun exposure 13. Dapsone causes no photosensitivity at all, making it the safest topical for outdoor lifestyles.

The two agents complement each other well. A 12-week study of adapalene 0.1%/benzoyl peroxide 2.5% combined with dapsone 5% gel (N = 443) showed that the combination produced superior reductions in both inflammatory and non-inflammatory lesions compared with adapalene/BPO alone 14. The combination was well tolerated, with no increase in local skin reactions beyond what each agent causes individually.

Dapsone vs. Tazarotene (Tazorac)

Tazarotene is the most potent topical retinoid approved for acne and is the only one also FDA-approved for psoriasis. It selectively binds RAR-beta and RAR-gamma with high affinity. A 12-week RCT comparing tazarotene 0.1% cream with tretinoin 0.05% cream found tazarotene superior for comedone reduction (P = 0.02) but associated with more frequent peeling and burning 15.

This potency-irritation tradeoff is exactly where dapsone fills a gap. Tazarotene is poorly tolerated in eczema-prone or sensitive phenotypes. The short-contact approach (applying tazarotene for 1 to 5 minutes then washing off) partially mitigates irritation 16, but this adds complexity. Dapsone gel requires no such workarounds.

A practical pairing used in clinical practice: tazarotene at night for its strong comedolytic effect and dapsone in the morning for anti-inflammatory coverage without stacking two irritants. No RCT validates this specific regimen, but the AAD guidelines support multi-mechanism combination therapy as a general acne principle 7.

Dapsone vs. Trifarotene (Aklief)

Trifarotene 0.005% cream, approved by the FDA in 2019, is the first topical retinoid designed for acne on the face and trunk simultaneously 17. It selectively agonizes RAR-gamma, the most abundant retinoic acid receptor in skin, achieving efficacy with lower systemic exposure than earlier retinoids. The PERFECT trials (two Phase III RCTs, N = 2,420) showed trifarotene reduced facial inflammatory lesions by 55.3% and trunk inflammatory lesions by 57.4% at 12 weeks vs. vehicle 18.

Trifarotene's local irritation profile falls between adapalene and tazarotene. Scaling occurred in 8.3% of trifarotene patients vs. 2.5% on vehicle in the PERFECT trials 18. Dapsone gel again shows the mildest profile, but trifarotene covers truncal acne where dapsone has limited trial data.

For patients presenting with combined facial and truncal acne, trifarotene addresses both sites with a single product. For facial-only acne in irritation-sensitive individuals, dapsone is preferred. The two are not typically combined, given the limited evidence, though their mechanisms do not overlap.

Side Effects and Safety of Topical Dapsone

The most common adverse events with dapsone 7.5% gel in clinical trials were dryness (3.3%), peeling (2.2%), and erythema (1.6%), rates comparable to vehicle 4. Contact dermatitis occurs rarely and is typically allergic rather than irritant. The absence of a retinization phase represents one of dapsone's strongest clinical selling points.

The principal concern inherited from oral dapsone is hemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients. Reassuringly, pharmacokinetic studies of the topical formulation show that systemic dapsone levels remain far below the concentrations that trigger hemolysis with oral dosing (typically >2 mcg/mL). The FDA label does not require G6PD testing before topical use, though it recommends consideration in patients with known deficiency 3. A post-marketing safety analysis covering more than 5 million prescriptions identified no cases of clinically significant methemoglobinemia or hemolytic anemia 19.

One important drug interaction: applying dapsone gel together with benzoyl peroxide can cause a temporary orange-brown discoloration of the skin. This is a cosmetic issue, not a safety concern, caused by oxidation of dapsone by benzoyl peroxide 20. Separating application times (BPO in the morning, dapsone at night, or vice versa) prevents this staining entirely. The 7.5% gel formulation appears less prone to this interaction due to its modified vehicle.

Who Should Consider Topical Dapsone?

Dapsone gel is best suited for specific patient profiles. Patients with inflammatory-predominant acne (papules and pustules more than comedones) respond most favorably based on the AAD's evidence review 7. Women with adult-onset acne, particularly those with hormonal flare patterns, show a pronounced response, consistent with the sex-stratified subgroup data from the key trials 6.

Patients who have failed or cannot tolerate topical retinoids gain a non-retinoid option with a distinct mechanism. Those with darker Fitzpatrick skin types (IV through VI) who are at high risk for retinoid-induced post-inflammatory hyperpigmentation may benefit from dapsone's low irritation potential 21.

Dapsone is also a rational add-on for patients already using a retinoid. The combination of adapalene and dapsone showed additive benefit without additive irritation 14. For patients on systemic therapies like spironolactone or oral antibiotics who want a topical anti-inflammatory component, dapsone integrates easily without photosensitivity or antibiotic-resistance concerns.

One population where dapsone is less ideal: patients with purely comedonal acne (blackheads and whiteheads with no inflammatory component). Retinoids outperform dapsone for this presentation. Start with adapalene 0.1% gel for comedonal acne in a retinoid-naive patient, and reserve dapsone for inflammatory disease or retinoid-intolerant cases.